FDA Clears First Transseptal Mitral Valve, Expanding Options for Patients

Edwards Lifesciences announced today that the U.S. Food and Drug Administration has approved its SAPIEN M3 transcatheter mitral valve replacement system for the treatment of symptomatic moderate to severe or severe mitral regurgitation in patients judged unsuitable for surgical mitral valve repair or replacement or for transcatheter edge to edge repair. The company said the approval also covers symptomatic mitral valve dysfunction associated with mitral annular calcification. Edwards framed the clearance as a major expansion of its structural heart portfolio.

The SAPIEN M3 system uses a transseptal, fully percutaneous delivery route in which a small puncture through the intra atrial septum allows catheter passage from the right atrium into the left atrium. The procedure, as described by the company, involves a dock delivery followed by valve delivery that fully replaces the native mitral valve. Edwards noted that the device previously received CE Mark clearance in April 2025, and called SAPIEN M3 the world’s first transfemoral transcatheter mitral valve replacement system.

Company executives said the approval will broaden the pool of patients who can be treated with minimally invasive techniques. In company materials Daveen Chopra, corporate vice president for transcatheter mitral and tricuspid therapies, said, "Over our more than 65 year history, Edwards has continued to push the boundaries of structural heart innovation." The firm’s U.S. transcatheter portfolio already includes the PASCAL Precision mitral valve repair system and the EVOQUE tricuspid valve replacement system.

Clinicians and regulators based the approval on clinical evaluations that the company and independent investigators described as showing favorable performance in reducing significant mitral regurgitation and improving symptoms among treated patients. Specific trial statistics were not provided in the company announcement. The ENCIRCLE clinical experience has been cited by investigators as a key source of data supporting the device, but detailed outcome metrics and long term durability data will be clarified in the FDA summary of safety and effectiveness that accompanies the approval.

The clearance marks a regulatory milestone for transcatheter mitral therapy and carries immediate public health and policy implications. Patients who are ineligible for open heart surgery or for transcatheter edge to edge repair have had few alternatives, particularly those with severe annular calcification or multiple comorbidities that raise surgical risk. A fully percutaneous transseptal option promises shorter recovery times and may reduce the burden of hospitalization, but it also raises questions about equitable access, coverage, and clinician training.

Wider availability will depend on insurer reimbursement decisions, hospital credentialing, and the capacity of regional centers to adopt a new, technically demanding procedure. Rural hospitals and safety net systems may lag in offering the technology, deepening existing disparities in access to advanced cardiac care. Regulators and health systems will need to monitor real world outcomes, device durability, and complication rates as use expands beyond clinical study populations.

The FDA approval is likely to stimulate further investment and competition in mitral therapies, and it underscores a broader shift toward less invasive structural heart interventions. For patients who previously had no suitable options, SAPIEN M3 offers a new pathway to symptom relief, but meeting its promise will require attention to safety data, training, and equitable delivery of care.